Hart Blik . nl - Gezien vanuit het hart!
John Jacobs
  • John
    • Over mij
    • About me
  • COVID-19 overzicht
    • Covid is niet voorbij
    • Oversterfte in Europa
    • Groepsimmuniteit weer opnieuw bekeken >
      • ​1. Over groepsimmuniteit. Giwob
      • 2. Drie mislukte pogingen. GIwob
      • ​3. Bereken de kosten. GIwob
      • 4. Onvolledige immuniteit. Giwob
      • 5. Wat zou er mis kunnen gaan? GIwob
      • 6. Wat kunnen we doen? GIwob
      • 7. Kort & krachtig! GIwob
    • Simpel&complex
    • Viruscontrole
    • Meer negativiteit
    • Epidemie controle
    • 2jaar-COVID19
    • Humanitair
    • Vragen >
      • Vragen over ziekte
      • Vragen over vaccins
      • Vragen over immuniteit
      • Vragen over Epidemie
      • Vragen over mutaties
      • Vragen over politiek
    • Gezondheidsraad
    • VirusEthiek >
      • Effectief en open strijden
      • Gaan we voor het goede?
      • Ziektecijfers
      • Vaccinatie
      • Preventie besmettingen
    • Virusmutaties
    • Bijzondere immuniteit
    • infectie zonder ziekte
    • Onnavolgbaar beleid dat verkeerd uitpakt >
      • Hoe goed bestrijden we COVID-19 ?
      • Gevaarlijk
      • Stoppen
      • Zijn de vaccins goed?
      • Beschermen vaccins tegen infectie?
      • Maakte Nederland de juiste keuzes?
      • Achterkamertjes geheimen
      • Wat zou Nederland moeten gaan doen?
      • Kanttekeningen
    • Afweer en vaccin >
      • IFR
      • Immuunreacties
      • Verschillende vaccins
      • Studies en resultaten
      • Een vaccin en dan?
    • Vaccinatieplan
    • Epidemiebestrijding herzien >
      • Epidemiebestrijding herzien. Strategie
    • Test, traceer & isoleer
    • Palet aan testen
    • Besmetting voorkomen
    • Geen groepsimmuniteit
    • Geen vaccin
    • Ziekte COVID-19
    • Advies VWS
    • 1953 versus 2020
    • Onder de loep >
      • RIVM virus bestrijding
    • Dwalen op bekend terrein
    • Dashboard >
      • Dashboard. I
    • Humanitair
    • Foute afweer
    • Betere bestrijding van de epidemie >
      • Beter (A) Impact COVID-19
      • Beter (B) Tussen complot en kritiekloos
      • Beter (C) Verschillende strategieën
      • Beter (D) Vaccin of beter maken
    • Cijfers en data >
      • Mutations
    • Bestrijding COVID19
    • Mondkapjes
    • Model leren voor beter handelen >
      • Model leren voor beter handelen 3
      • Model leren voor beter handelen 4
      • Model leren voor beter handelen 5
      • Model leren voor beter handelen 6
      • Model leren voor beter handelen 7
    • Verloren door te weinig kennis
    • Ontelbaar op waarde geschat
    • Rekenen zonder getallen
    • Versimpeld model Corona NL >
      • Addendum. Correctie
      • Erratum
    • FAQ - COVID-19 >
      • FAQ. Epidemie
      • FAQ. Model
      • FAQ. Bestrijding
      • FAQ. Ziekte
      • FAQ. Coronavirussen
    • Reacties
    • Immuniteit en antistoffen >
      • Rekenen zonder getallen 7
      • Model leren voor beter handelen 2
    • Platform BZC
  • Medisch & biologie
    • Schepping & evolutie
    • Schepping verbeteren
    • Niet-sterieliserende slijmvlies immuniteit
    • Willem den Otter. In Memoriam
    • Luchtvervuiling doodt >
      • Luchtvervuiling doodt1
      • Luchtvervuiling doodt. 2
      • Luchtvervuiling doodt. 3.
      • Luchtvervuiling doodt. 4.
      • Luchtvervuiling doodt. 5.
    • Voorkom epidemie
    • Expert opinion
    • Ongezonde gezondheid
    • HPV
    • Ontsnappende virussen
    • Eiwit evolutie >
      • Afweer ontwerp
    • Tumor immunologie
    • Huidveiligheid
  • Samenleving
    • Schepping & evolutie
    • Schepping verbeteren
    • ORTEC blogs >
      • P4O2-COVID19
      • U-Prevent
      • Clinical decision support
      • Data voor betere patiëntenzorg
    • Licht & helderheid verschaffen.
    • AI summerschool (NL)
    • Racisme
    • Kwaadaardig complotten
    • Drie complotten
    • Bang
    • Onvrede en vrede
    • Schoppentroef
  • Federa
    • Federa deelnemers
  • English blogs
    • Covid is not over
    • ExcessMortalityEEA
    • Effective and open
    • Range of tests
    • SupplementEM
    • Virus Ethics >
      • Do we strife for the good things?
      • Disease outnumbered
      • Special immunity
      • Vaccination
      • Immune responses and vaccin >
        • Immune responses
        • Different vaccines
        • Trials and results
        • Next steps
        • Prevention of epidemic
        • Vaccinationwise
    • Non-sterile mucosal immunity
    • Contamination
    • No herd immunity >
      • Questions on COVID-19 >
        • Disease
        • Vaccine >
          • Immunity
        • Epidemics
        • Poltics
        • IFR
    • Test, trace & isolate
    • No vaccine
    • Disease
    • Lost at familiar property
    • Corona Dashboard
    • Fighting COVID19
  • ORTEC in English
    • P4O2-COVID19
    • Data science for better treatment of leukemia.
    • U-Prevent [EN]
    • Clinical decision support [EN]
    • Data to improve patient care
  • Linkpagina

COVID-19

Foto
Foto

Immune responses and vaccines

Vaccination and next steps

John Jacobs, 28.11.2020

Foto

COVID-19 strikes hard in society. Some people consider the health of diseased and elderly people to be less relevant. It brings flash backs to the dark pages in European history. Personally, I know several people who had fatal COVID-19 and not all were old. A medical risk group is not the same as only the diseased and elderly. I personally knew a man in his fifties who passed away, but prior his disease he was still an active worker albeit having an increased BMI. People with a risk of cardiovascular disease do not always know this. Diabetes is also a risk factor. Diabetes and cardiovascular disease can also be the result from SARS-2 infection. A previously healthy person might have an increased risk after the first infection and be at increased risk of fatality upon reinfection.
​
No vaccine will protect everyone. The advertisements of Pfizer and Moderna herald over 90%; AstraZeneca says 70%; but according their protocol it is only 62%. Vaccines are likely to be less effective in elderly, because (i) of immunosenescence, (ii) the data from the AstraZeneca study, and (iii) the expert opinions like Marion Koopmans’. After vaccination, infection fatality ratio might fall to influenza-like levels, but could also be a bit higher, despite vaccination. Vaccines are a good asset, but not a magic bullet that would offer full protection form disease for everyone.

To vaccinate or not to vaccinate?

This question will not be resolved by press releases, but by the EMA decisions on submitted scientific data of RCTs. If vaccines indeed protect 90% protection without serious side effects, they would be well beyond expectations. Data science insights strongly suggests that such a huge effect should also be visible and probably significant on serious COVID-19, if the vaccine also offers effective protection against disease worsening. Most likely the EMA will also investigate this. 90% effectiveness would reduce the average death from COVID-19 from over 0.9% to 0.1%. That is slightly higher than the most severe waves of influenza.
​
How long will protection by a corona vaccine last when natural corona cold virus immunity only protects for a few months? The current RCTs cannot answer this question, because the only have a few months of follow up. T cells seem to persist longer after SARS-1, but we do not know if it suffices for protection. The proof of the pudding is in the eating: immunity is determined by (natural) exposure and not by immune parameters.

Looking forwards

In brief, I think that a vaccine that cause a relevant reduction of COVID-19 mortality. We should not rely levels of antibody responses. People who are admitted to a hospital have 10 to 30 times as high antibody levels compared to those who remain ill at home (Figure 13). Infection and virus secretion in children occurs as often in adults, but they have less often (serious) disease and, according to Dutch research, also rarely have antibodies (Figure 14). The immunology of coronaviruses differs from many other viruses and is only partially understood. It can be argued that not every vaccine under development will have a positive effect on health, and some may have a negative effect and in exacerbating the disease. This should always be considered, especially when novel vaccines are produced according to different immunological principles. Europe should wait for the scientific data to be evaluated by the EMA.

After registration, the vaccine manufacturers should produce sufficient vaccines, and governments should mount an unprecedented logistical operation to vaccinate everyone. An optimistic estimate says this will be finished by the end of 2021. The question then is how long the vaccine protects, hopefully longer than the protection after infection.

Meanwhile, it is crucial to limit the epidemic and its impact terms of morbidity and mortality. Vaccines are unlikely to help limit the spread of disease since the immunity they induce is not sterilizing and will not yield herd immunity. People could be protected by lockdown measures, but the combination of testing, tracing and isolation has been proven to be more effective and better for society and economy. Safety of vaccines is only evaluated in people free of a COVID-19 infection.

Foto
Figure 13. Antibody levels in people admitted to hospital (red) and not (black).
N = nucleoprotein; S1 part of Spike protein. RBD is the receptor binding domain of the Spike protein.


Foto
Figure 14. Percentage of people with antibodies at different ages


Foto

Immune responses and vaccines
Immune responses
Different vaccines
Trials and results
Vaccination and next steps
Foto

John Jacobs
28 november 2020

Powered by Maak je eigen unieke website met aanpasbare sjablonen.